The APGI is based at the Garvan Institute of Medical Research in Sydney and the Institute of Molecular Bioscience in Brisbane. Our collaborators include pancreatic cancer healthcare professionals in major cities across Australia. We also have international links with major pancreatic healthcare research centres in the USA, Canada and Italy.
The APGI is jointly led by Professor Andrew Biankin at the Garvan Institute of Medical Research in Sydney and Professor Sean Grimmond at the Institute of Molecular Bioscience in Brisbane.
Professor Biankin is a surgeon scientist who specializes in Pancreatic Diseases, particularly focusing on Pancreatic Cancer and its precursor lesions. His clinical practice is part of a specialist unit treating pancreatic disease in Sydney. His research is focused on translating scientific discoveries into patient care through improved application of current therapies, early detection and novel therapeutics.
Professor Sean Grimmond is Director of the Queensland Centre for Medical Genomics, located at the Institute for Molecular Bioscience, The University of Queensland. His research over the last decade has focused on defining the molecular networks controlling biological processes and pathological states through genome-wide surveying of sequence content, transcriptome complexity and epigenomic signatures. His scientific achievements include the pioneering of array-based and sequence-based technologies, the functional annotation of mammalian transcriptomes and the study of transcriptional programs in cancer and urogenital development.
Our collaborators include pancreatic cancer experts in major hospitals and research facilities across the country. This project would not be possible without the dedication and support of each and everyone mentioned here. From the APGI team, a very big thank you to all!
Biospecimens are the link between molecular biology and cancer research. They allow researchers to study genomic and epigenomic abnormalities in the context of cancer disease development and progression.
The purpose of genome-wide survey of cancer cells is the identification of driver mutations which are key to the development of cancer at the cellular level.
Are you enrolled in the APGI project? Or do you have a loved one enrolled with us? Keep up to date with what's happening at APGI with our biannual community newsletter series.
The APGI would not be possible without the support of our collaborators nationwide. If you're an APGI collaborator, keep up to date with our clinical newsletter series.
We are seeing great progress in pancreatic cancer research and the APGI and it's collaborators are at the heart of this.
The APGI has provided coded clinical data and biological resources to many institutions and researchers to help further pancreatic cancer research worldwide.